ArticleBritish journal of cancer2009
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis.Frontiers in cell and developmental biology · 2020Pooled it
- Five endometrial cancer risk loci identified through genome-wide association analysis.Nature genetics · 2016Pooled it
- Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.Gynecologic oncology · 2019Trial
- Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.Gynecologic oncology · 2016Trial
- The structural heterogeneity of AKT autoinhibition.Protein science : a publication of the Protein Society · 2026Article
- Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design.Discover oncology · 2025Article
- Targeting Mutant Protein Kinase B with Lysine-Selective Salicylaldehyde Inhibitors and ZnMolecular biomedicine · 2025Article
- AKT kinases as therapeutic targets.Journal of experimental & clinical cancer research : CR · 2024Review
- mTOR Pathway Inhibition, Anticancer Activity and In Silico Calculations of Novel Hydrazone Derivatives in Two- and Three-Dimensional Cultured Type 1 Endometrial Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Could cannabinoids provide a new hope for ovarian cancer patients?Pharmacology research & perspectives · 2023Review
- Localized heterochrony integrates overgrowth potential of oncogenic clones.Disease models & mechanisms · 2023Article
- Genomic landscape of endometrial carcinomas of no specific molecular profile.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- The AKT1E17K Allele Promotes Breast Cancer in Mice.Cancers · 2022Article
- Short-chain L-3-hydroxyacyl-CoA dehydrogenase: A novel vital oncogene or tumor suppressor gene in cancers.Frontiers in pharmacology · 2022Review
- Akt: A Potential Drug Target for Metabolic Syndrome.Frontiers in physiology · 2022Review
- Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.BMC cancer · 2021Article
- Targeting Akt in cancer for precision therapy.Journal of hematology & oncology · 2021Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe phosphatidylinositol 3'-kinase (PI3K)-AKT pathway is activated in many human cancers and plays a key role in cell proliferation and survival. A mutation (E17K) in the pleckstrin homology domain of the AKT1 results in constitutive AKT1 activation by means of localisation to the plasma membrane. The AKT1 (E17K) mutation has been reported in some tumour types (breast, colorectal, ovarian and lung cancers), and it is of interest which tumour types other than those possess the E17K mutation.
methodsWe analysed the presence of the AKT1 (E17K) mutation in 89 endometrial cancer tissue specimens and in 12 endometrial cancer cell lines by PCR and direct sequencing.
resultsWe detected two AKT1 (E17K) mutations in the tissue samples (2 out of 89) and no mutations in the cell lines. These two AKT1 mutant tumours do not possess any mutations in PIK3CA, PTEN and K-Ras.
interpretationOur results and earlier reports suggest that AKT1 mutations might be mutually exclusive with other PI3K-AKT-activating alterations, although PIK3CA mutations frequently coexist with other alterations (such as HER2, K-Ras and PTEN) in several types of tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.